At1g73610 Antibody
Description
Antibody Structure and Function
Antibodies are Y-shaped glycoproteins produced by B cells to neutralize pathogens or foreign substances. They consist of two heavy chains (H) and two light chains (L), forming variable (V) and constant (C) regions. The variable region includes complementarity-determining regions (CDRs) that bind antigens with high specificity .
Afucosylated Antibodies: Enhanced Effector Functions
Afucosylated antibodies lack fucose residues in their Fc region, enhancing interactions with FcγIIIa receptors on natural killer (NK) cells. This modification increases antibody-dependent cellular cytotoxicity (ADCC), a critical mechanism in cancer immunotherapy .
Key Applications:
-
Cancer: Targeting tumor-specific antigens (e.g., CD20 in lymphoma) .
-
Autoimmune Diseases: Reducing inflammation via selective ADCC .
-
Infectious Diseases: Neutralizing pathogens with high precision .
Broadly Neutralizing Antibodies Against Influenza
Anti-neuraminidase (NA) antibodies, such as 1G01, exhibit broad cross-reactivity against influenza A and B viruses. These antibodies inhibit NA activity (IC₅₀ = 7.62 nM for Fab fragments) and neutralize viral replication in vitro and in vivo .
Antibodies in GPCR Modulation
Nanobodies (single-domain antibodies) targeting the angiotensin II type 1 receptor (AT1R) demonstrate maternal selectivity. Engineered variants (e.g., AT118-L) inhibit AT1R signaling while avoiding placental transfer, offering therapeutic potential for hypertension in pregnancy .
Mechanistic Insights:
-
Allosteric Antagonism: Nanobodies bind extracellular domains, altering receptor conformation to block angiotensin II signaling .
-
Tissue-Specific Action: Fc engineering prevents neonatal Fc receptor (FcRn) binding, restricting activity to maternal circulation .
Hypothetical Role of At1g73610 Antibody
If At1g73610 encodes a plant protein or a conserved eukaryotic protein, antibodies against it might:
-
Study Protein Localization: Immunofluorescence or Western blotting to map subcellular distribution .
-
Regulate Pathways: Inhibit enzymatic activity (e.g., kinase or receptor) if At1g73610 is functional .
-
Diagnostic Use: Detect biomarkers in disease states (e.g., autoimmune disorders or cancer) .
Challenges and Future Directions
The absence of literature on At1g73610 Antibody suggests:
Product Specs
Composition: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Target Background
Q&A
At1g73610 Antibody: Research-Focused FAQs
(Generated from academic literature and technical documentation analysis)
Advanced Experimental Design
-
Resolving contradictory results between qRT-PCR and Western Blot data using At1g73610 Antibody
-
Systematic troubleshooting protocol:
-
Verify RNA integrity (RIN >8.0) and protein extraction efficiency
-
Test antibody performance across diurnal cycles (protein may show circadian oscillations)
-
Perform cross-validation with independent antibody (e.g., Agrisera AS12 1852)
-
-
-
Designing co-immunoprecipitation experiments for At1g73610 interactome studies
-
Critical parameters:
-
Lysis Buffer: 50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.5% NP-40, 1× protease cocktail
-
Crosslinker Comparison:
Agent Efficiency Elution DSP 85-90% 50 mM DTT Formaldehyde 70-75% 95°C/10min
-
-
Data Interpretation Challenges
-
Differentiating between true signal and background in root tip immunostaining
-
Confirm spatial pattern reproducibility across ≥3 biological replicates
-
Statistical approaches for temporal expression analysis
-
Use mixed-effects models to account for:
-
Batch effects in protein extraction
-
Non-normal distribution of fluorescence intensities
-
Plant-to-plant developmental variability
-
-
Methodological Recommendations
-
Always include biological and technical negative controls when studying post-translational modifications
-
For phospho-specific applications, treat samples with λ-phosphatase (400U/μl, 30min at 30°C) as specificity control
-
Validate antibody lot consistency through annual performance metrics (CV <15% for signal intensity)
